Science – bought and paid for.

Dr. Weeks’ Comment: When people say “follow the science” the assumption is that the scientists do NOT have conflicts of interest. What follows is TYPICAL for peer reviewed scientific publications…

Conflict of interest statement

Conflict of Interest Disclosures: 

Dr Nicholls reported receiving grants from AstraZeneca, Amgen, Anthera, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi-Regeneron, and LipoScience; and receiving personal fees from AstraZeneca, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion, and Boehringer Ingelheim during the conduct of the study.

Dr Lincoff reported receiving grants from AstraZeneca during the conduct of the study, and Esperion, Novartis, CSL, and AbbVie outside the submitted work; and personal fees from Novo Nordisk and Eli Lilly. Dr Garcia reported receiving grants from Cleveland Clinic during the conduct of the study.

Dr Ballantyne reported receiving personal fees from AstraZeneca during the conduct of the study; grants from Akcea, Amgen, Esperion, Novartis, and Regeneron; and personal fees from Akcea, Althera, Amarin, Amgen, Arrowhead, Corvidia, Denka Seiken, Esperion, Gilead, Janssen, Matinas BioPharma Inc, New Amsterdam, Novartis, Novo Nordisk, Pfizer, Regeneron, and Sanofi-Synthelabo outside the submitted work.

Dr Davidson reported receiving personal fees from AstraZeneca during the conduct of the study; and was the founder and chief medical officer of Omthera Pharmaceuticals that developed Epanova, acquired by AstraZeneca in 2013; from 2013 to 2015, Dr Davidson was an employee of AstraZeneca and worked for the NDA submission and FDA approval of Epanova as well as the initiation of the STRENGTH trial. Since 2015, Dr Davidson has served on the steering committee of STRENGTH and received a $10 000 yearly honorarium since 2015 but has not received nor will receive additional monetary compensation for Epanova.

Dr Kastelein reported receiving personal fees from AstraZeneca, CSL-Behring, Esperion, Matinas Biopharma, Novartis, Novo Nordisk, Omeicos, Pfizer, Regeneron, and 89Bio outside the submitted work.

Dr Koenig reported receiving personal fees from AstraZeneca, Novartis, Pfizer, The Medicines Company, DalCor, Kowa, Amgen, Corvidia, Daiichi-Sankyo, Berlin Chemie, Sanofi, and Bristol-Myers Squibb; Dr Koenig also reported receiving grants and nonfinancial support from Singulex, Abbott, Beckmann, and Roche Diagnostics outside the submitted work.

Dr McGuire reported receiving personal fees from AstraZeneca during the conduct of the study; personal fees from Boehringer Ingelheim, Sanofi, AstraZeneca, Merck & Co, Novo Nordisk, Esperion, Lexicon, Lilly USA, GlaxoSmithKline, Applied Therapeutics, Metavant, and Afimmune outside the submitted work; and nonfinancial support from Pfizer.

Dr Mozaffarian reported receiving personal fees and other from Cleveland Clinic Foundation during the conduct of the study; grants from National Institutes of Health, Gates Foundation, and Rockefeller Foundation; personal fees from GOED, Danone, Indigo Agriculture, Motif FoodWorks, Amarin, Acasti Pharma, and America’s Test Kitchen; serving on the scientific advisory board for Beren Therapeutics, Brightseed, Calibrate, DayTwo, Elysium Health, Filtricine, Foodome, HumanCo, January.ai, and Tiny Organics; and receiving chapter royalties from UpToDate outside the submitted work.

Dr Ridker reported receiving grants from Kowa and Amarin during the conduct of the study; and personal fees from Novartis, Flame, Janssen, AstraZeneca, Agepha, Corvidia, Omeicos, CiviBio, and Inflazome outside the submitted work.

Dr Ray reported receiving personal fees from C5 during the conduct of the study; consulting fees from Abbott, Kowa, Lilly, Akcea, Medicines Company/Novartis, Novo Nordisk, Boehringer Ingelheim, Bayer, Esperion, Resverlogix; and grants and consulting fees from Daiichi Sankyo, Amgen, and Sanofi/ Regeneron, outside the submitted work.

Dr Katona reported owning shares in AstraZeneca during the conduct of the study. Dr Himmelmann reported owning shares in AstraZeneca outside the submitted work. Dr Loss reported owning stock in AstraZeneca outside the submitted work. Dr Rensfeldt reported other from AstraZeneca during the conduct of the study; other from AstraZeneca outside the submitted work. Ms Wolski reported receiving grants from AstraZeneca during the conduct of the study.

Dr Nissen reported receiving grants from AstraZeneca during the conduct of the study; grants from Novartis, Abbvie, Silence Therapeutics, Medtronic, MyoKardia, Esperion, Eli Lily, Amgen, Novo Nordisk, Pfizer, Cerenis, and The Medicines company outside the submitted work. No other disclosures were reported.

Leave a Comment

Your email address will not be published. Required fields are marked *